On Aug. 12, 2020, Baxter announced it had received Emergency Use Authorizations (EUAs) from the FDA for the companyﾒs HF20 Set and ST Set used in continuous renal replacement therapy (CRRT). Under its EUA, the HF20 Set is authorized to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the COVID-19 pandemic.